Table 4. The response rate to second-line CDDP based chemotherapy and second-line CDDP analogue based chemotherapy.
| Variable | CDDP based (n=23) | CDDP analogue based (n=26) | ||
|---|---|---|---|---|
| RR (%) | p-value | RR (%) | p-value | |
| Age (yr) | 0.772 | 0.907 | ||
| ≤50 | 20.0 | 18.2 | ||
| >50 | 15.4 | 20.0 | ||
| Histology | 0.191 | 0.184 | ||
| Squamous cell carcinoma | 23.5 | 11.8 | ||
| AC/ASC | 0 | 33.3 | ||
| Stage at initial diagnosis | 0.022 | 0.778 | ||
| I-II | 36.4 | 22.2 | ||
| III-IV | 0 | 17.6 | ||
| Prior radiotherapy | 0.026 | 0.25 | ||
| Yes | 100 | 50.0 | ||
| No | 13.6 | 16.7 | ||
| Pelvic disease | 0.315 | 0.907 | ||
| Yes | 9.1 | 18.2 | ||
| No | 25.0 | 20.0 | ||
| Tumor diameter (mm) | 0.412 | 0.562 | ||
| <30 | 23.1 | 22.2 | ||
| ≥30 | 10.0 | 21.5 | ||
| PFI<6months | 0.191 | 0.373 | ||
| Yes | 0 | 27.3 | ||
| No | 23.5 | 13.3 | ||
| PFI<12months | 0.006 | 0.961 | ||
| Yes | 0 | 19.0 | ||
| No | 44.4 | 20.0 | ||
AC/ASC, adenocarcinoma/adenosquamous cell carcinoma; CDDP, cisplatin; CI, confidence interval; HR, hazard ratio; PFI, platinum free interval; RR, response rate.